The present study was undertaken to study the mechanism of cyclosporine-induced nephrotoxicity and hypertension. Cultured rat microvascular endothelial cells were exposed to cyclosporine for up to six days at one of the following concentrations: 10, 50, 250, and 1000 nglml of culture medium. Cyclosporine inhibited endothelial cell replication in a dose.dependent manner; at higher concentrations (250 and 1000 ng/ ml), cell replication decreased by as much as 70 to 90% of controls at four and six days post-treatment, with no evidence of increased cell death. Drug-treated endothelial cells revealed abnormal morphological changes such as formation of cytoplasmic vesicles and nucleolar changes. Prostacyclin release by endothelial cells was increased by about threefold with the addition of cyclosporine (P < 0.01). Indomethacm significantly decreased prostacyclin release by endothelial cells in the presence or absence of cyclosporine (P < 0.01). Our data suggest that cyclosporine-induced nephrotoxicity may be mediated, at least partly, by the inhibitory influence of cyclosporine on the regenerative response of microvascular endothelial cells to injury, and the resultant alterations in prostacyclin production by these cells.
Cyclosporin A, an active endecapeptide of fungal origin, is a potent immunosuppressive agent in widespread use for prolonging the survival of various allogeneic organ transplants [1] [2] [3] [4] . Its immunosuppressive action is predominantly mediated by the inhibition of T-helper cell production of interleukin 2, a T-ceIl growth factor essential for B cell and cytotoxic T cell proliferation [1, 2] . While it has become the immunosuppressant of choice in clinical transplantation in the eighties, cyclosporine therapy can be complicated by several adverse effects including nephrotoxicity, hepatotoxicity, and hypertension [1] [2] [3] [4] [5] [6] [7] . Of all the known complications, nephrotoxicity is the most frequent and clinically important, and may ultimately limit the use of cyclosporine [5] [6] [7] [8] . Cyclosporine-induced nephrotoxicity is often accompanied by decreased glomerular filtration rate and proximal tubular damage [7, 81 . The morphological changes range from toxic tubulopathy manifested by nonspecific vacuolization, swelling of endoplasmic reticulum and mitochondria in tubular epithelial cells, to capillary congestion and arteriolopathy [7] [8] [9] [10] . In an animal model, cyclosporine treatment induced endothelial injury, capillary thrombosis, and glomerular infarction similar to that seen in a generalized Schwartzman Received for publication August 26, 1987 and in revised form September 2, 1988 © 1989 by the International Society of Nephrology reaction [11, 12] , This and other reports have led some investigators to propose that cyclosporine inhibits the synthesis of a prostacyclin-stimulating factor in the kidney, thereby leading to decreased production of prostacyclin by endothelial cells [11] [12] [13] . Prostacyclin is a potent antagonist of thromboxane-mediated platelet aggregation and subsequent thrombosis; it also plays an important role in renal autoregulation by acting as a physiologic antagonist to the vasoconstrictive effect of angiotensin II [14] [15] [16] . Thus, decreased prostacyclin production may partly explain the hypertension and accelerated renal arteriolar lesions induced by cyclosporine. Although it appears that endothelial injury is an important feature of cyclosporineinduced nephrotoxicity, the mechanism of cyclosporine-induced nephrotoxicity clearly requires further elucidation. The purpose of the present study was to examine whether cyclosporine has a direct influence on the growth, morphological, and biochemical characteristics of microvascular endothelial cells in culture.
Methods
Isolation and culture of adipose microvascular endothelial cells Microvascular endothelial cells were isolated from retroperitoneal adipose tissue of adult male Sprague-Dawley rats (150 to 200 g) as reported previously [171. Briefly, fat tissue resected aseptically from rats was digested with 0.5 mg/mI collagenase (Type I, Worthington Biochemicals, Freehold, New Jersey, USA) in Hanks' balanced salt solution (HBSS) for 30 minutes at 37°C, with continuous agitation in a gyrotory waterbath shaker (New Brunswick Scientific, Edison, New Jersey, USA). The cell suspension was filtered through a 250 pm nylon sieve (Nitex) to remove undigested fat, and the filtrate was centrifuged at 300 x g for 10 minutes. The cell pellet was resuspended in alpha minimum essential medium (MEM) supplemented with 10% fetal bovine serum (FBS) (Gibco Canada, Burlington, Ontario, Canada), and antibiotics (penicillin 100 mg/ml and streptomycin 50 mg/ml). Adipocyte precursors were separated from the endothelial cell clumps by passing the cell suspension through a 25 m nylon mesh (Nitex). The endothelial cell clumps left on the sieve were inoculated into culture vessels (Corning Culture Products, Corning, New York, USA) and grown in complete alpha MEM supplemented with 10% FBS, 15 mM HEPES, and antibiotics, in a humidified 95% air-5% CO2 atmosphere at 37°C. Colonies of endothelial cells formed in the first three to five days were detached from primary culture with the aid of cloning cylinders and 0.5 mg/mI trypsin-0.25 mi EDTA solution, and subcultured. Homogeneous cell strains of microvascular endothelial cells were obtained beginning with the first subculture [17] . Cells were grown to monolayer confluence and propagated in subcultures. Our cultured microvascular endothelial cells have been characterized and reported in detail [17] . Briefly, endothelial cells were distinguished by various markers: the characteristic cobblestone appearance on light microscopy and presence of WeibelPalade bodies on electron microscopic examinations; positive staining for Factor VIII antigen by immunofluorescence; and prostacyclin production by radioimmunoassay [17, 18] . In all the experiments described herein, microvascular endothelial cells between the second and fifth subcultures were used, and their Factor VIII antigen positivity was monitored regularly. Cultured rat skin fibroblasts and preadipocytes were used as negative controls for Factor VIII antigen staining.
Influence of cyclosporine on endothelial ce/i groo'th Cells were seeded at a density of 7,000 cells/cm2 into each well of 24-well plates, and grown in alpha MEM with 10% FBS.
Forty-eight hours later, cyclosporine (Sandoz, Montreal, PQ, Canada) 50 mg/mI in cremophor was diluted I: 100 with 50 mgI ml glucose solution and added immediately before use) was added in quadruplicates to each cell culture at one of the following concentrations: 10, 50, 250, or 1000 ng/ml of culture medium. The dose range of cyclosporine used in this study was similar to those used by others in cell culture studies [19] , and was within the peak and nadir therapeutic plasma levels reported in patients receiving the medication either orally or intravenously [20, 21] , Control cells were not exposed to cyclosporine; the corresponding volume of carrier (cremophor in 50 mg/mI glucose solution) was added instead. The growth, morphological, and biochemical characteristics of the endothehal cells were assessed in both control and drug-treated groups daily for a total of six days. Cell replication was assessed by both direct cell counting using a Model ZM Coulter counter (Coulter Electronics of Canada, Burlington. Ontario, Canada), and by incorporation of [methyl-3H]thymidine into trichloroacetic-acid-insoluble macromolecules (DNA), as previously described [17, 18, 221 suspension was transferred to a sampling manifold (Millipore Corporation, Bedford, Massachusetts, USA) fitted with Whatman GF/1 glassfiber filters, and was thoroughly washed with 30 ml 10% trichloroacetic acid. The radioactivity incorporated into the trichloroacetic-acid-insoluble macromolecules, which was retained on the filters, was counted in 5 ml Econofluor scintillation fluid (New England Nuclear, Lachine, PQ, Canada) in a LKB RackBeta liquid scintillation spectrophotometer (LKBProdukete AB, Bromma, Sweden).
Cell viability was assessed under light microscopy by quantifying the percentage of cells, using a hemocytometer, that actively excluded 0.1% Trypan blue dye in 0.9% saline [18] .
Electron microscopy Cultured cells were scraped off the culture dish with a rubber spatula and centrifuged at 300 x g for 10 minutes. The cell pellets were fixed for one hour at room temperature in 2.5% glutaraldehyde-l% osmium tetraoxide mixture in 0.1 M cacodylate-buffer, pH 7.4, containing 0.1 M sucrose and 5 mi CaCI2.
The samples were dehydrated through graded acetone and embedded in Epon. Selected areas were sectioned, stained with uranyl acetate and lead citrate, and examined in a Hitachi Model H600 electron microscope.
Effect of cyclosporine on Factor VIII antigen staining and prostacyclin synthesis by endothelial cells Prostacyclin (PGI2) production by cyclosporine-treated and untreated endothelial cells was quantified by the release into the culture medium of 6-keto-PGF1,, a stable catabolic product of PGI,, using a radioimmunoassay kit (Amersham Canada Ltd., Oakville, Ontario, Canada) [18] . Previous experiments were conducted to ensure that the amount of PG!2 assayed was well within the detectable range of 0.008 to 1.4 pmoh/ml. Briefly, 100 l aliquots of either standard solution or unknown were incubated with 100 d each of [3H]6-keto-PGF1, and 3,6-keto-PGF1 antiserum at room temperature for one hour, followed by another 16 to 20 hour incubation at 4°C. Dextran-coated charcoal was added to the assay tubes to bind the free 6-keto-PGF1,. Following centrifugation at 1000 x g for 10 minutes at 4°C, the amount of bound [3H]6-keto-PGF1 in the supernatant was quantified.
Since 10% FBS was required for optimal endothelial cell growth, we conducted separate experiments to determine whether FBS cross-reacted with the antibodies used in the PG!2 assay. We found that FBS did not interfere with the actual PGI2 assay.
To examine whether the cyclosporine-induced alterations in PGI, production was due to a change in its release or synthesis, we conducted a similar series of experiments, as described above, in the presence or absence of l0-M indomethacin, which is a known inhibitor of prostaglandin synthesis.
The influence of cyclosporine on the presence of Factor VIII antigen in endothelial cells was examined by an immunofluorescent staining technique [17] . For this study, microvascular endothelial cells were grown on glass cover slips. At 2, 4, or 6 days following drug treatment (at the four concentrations as described above), cells were washed with PBS and fixed in a solution containing a I: I mixture of glacial acetic acid and methanol. The cells were then washed thrice with PBS and incubated at 37°C with rabbit antiserum to human Factor VIII (Calbiochem, San Diego, California, USA) for about 16 to 20 hours. This was followed by a second incubation with a 1:20 solution of fluorescein-conjugated anti-goat IgG (Miles Laboratories, Inc., Naperville. Illinois, USA) at 37°C for one hour.
After extensive washings with PBS, the coverslips were mounted on glass slides with para-phenylenediamine mounting buffer [23] . Immunoreactivity to Factor VI!! was examined Using the unlabelled antibody peroxidase-antiperoxidase [24] or avidin-biotin-peroxidase complex [25] technique, the fixed slides were stained for vimentin, Factor VIII antigen, and for ulex europalus I (Dako Corporation, Santa Barbara, California, USA).
Statistical analysis All data were analyzed by Student's paired f-test, and for multiple comparisons, by Tukey's method [26] .
Results

Morphological observations
Under normal culture conditions, endothelial cells formed small colonies within two to three days following inoculation. By 12 to 20 days, depending on the initial inoculum density, these cells would reach monolayer confluence and display the characteristic cobblestone appearance (Fig. 1A) . There was no appreciable change in the light microscopic appearance of endothelial cells with low dose cyclosporine (10 to 50 nglml) treatment for six days. However, abnormal changes were readily observed in cells exposed to higher doses of cyclosporine (250 and 1000 ng/ml), as shown in Figure lB . Despite the morphological changes induced by cyclosporine, there was no evidence of cell death, as assessed by Trypan blue exclusion, even when the cells were exposed to the highest concentration of cyclosporine. In fact, cell viability was over 95% for both control and cyclosporine-treated cells throughout the entire study period, with no statistical differences in cell viability between cells on days 2 and 4, or between cells on days 2 and 6 of growth.
Light and electron microscopic examinations demonstrated presence of cytoplasmic vacuoles as early as 48 hours following drug exposure. These vacuolations appeared in greater number with increasing dosage and duration of exposure to cyclosporine (Fig. 2) . The vacuoles were bound by a single unit membrane containing either a small amount of amorphous materials occasionally mixed with dense granules, or membranous fragments with clusters of small organized round structures (Fig. 3) . Other cytoplasmic organelles, such as mitochondna, endoplasmic reticulum and Golgi apparatus, did not show any significant abnormalities. When cells were exposed to 250 ng/ml or 1000 nglml cyclosporine for six days, the nucleoli of some endothelial cells revealed segregation of nucleolar components, resulting in formation of many electron-lucent areas (Fig. 4) .
Factor VIII antigen staining Positive staining for Factor VIII antigen was present in both cyclosporine-treated and untreated (control) endothelial cells (Fig. 5 ), but not in control cells such as rat fibroblasts and preadipocytes (data not shown). Furthermore, neither the pattern nor the intensity of staining show any appreciable change with cyclosporine during the entire length of the six day study period.
Effect of cyclosporine on endothelial cell growth Figure 6 shows the inhibition of cell replication by cyclosporine expressed as a percent of control cells not exposed to the drug. Cell replication was determined by direct cell counting (Fig. 6A) and by incorporation of [3Hjthymidine into trichloroacetic-acid-insoluble macromolecules (DNA) (Fig. 6B) . As shown in this figure, cyclosporine inhibited the growth of microvascular endothelial cells in a dose-dependent manner.
With low dose (10 nglml) cyclosporine, the inhibitory effect was only evident after six days of incubation. However, significant inhibition was observed as early as two days following exposure to higher doses of cyclosporine. After six days of high-dose cyclosporine treatment (1000 nglml), cell replication, as assessed by direct cell enumeration and radioactive thymidine incorporation into DNA, decreased to 38% and 21% of control, respectively.
Prostacyclin release by microvascular endothelial cells Prostacyclin (PGI2) release by microvascular endothelial cells cultured in the absence or presence of cyclosporine is shown in Table 1 . In all cases the PG!2 present in the culture media was well within the detectable range of the radioimmunoassay, The level of PG!2 present in the control cells were comparable to that observed in endothelial cells from large vessels [24] . Hence the amount of arachidonate present in the 10% FBS added to all our cell culture media did not appreciably alter the basal state of PG!2 release by microvascular endothehal cells. Since the total amount of PG!2 release into the culture media increased progressively in all cells from days I to 6, we chose to show only the data from days 2, 4, and 6 in Tables I  and 2 . Statistically significant differences in PGI2 release by both the untreated controls as well as in the cyclosporinetreated cells were observed between 2 and 4 days, and between 4 and 6 days of growth. When comparing the PG!2 release by control and cyclosporine-treated cells, statistical differences were seen only in those cells exposed to high dose (250 and 1000 ng/ml) cyclosporine at 4 and 6 days of growth.
Since cyclosporine inhibited cell replication, the data were also analyzed by expressing PG!2 release on the basis of cell number instead of total amount present in each culture well. There was no statistical difference in PG!2 release by any one group of cells (control or drug-treated) between 2 and 4 days, between 2 and 6 days, and between 4 and 6 days of growth (Table 2) . However, major differences were observed when PG!2 release by control cells was compared with that by drug-treated cells. Cyclosporine stimulated PG!2 release by endothelial cells after four days of exposure in a dose-dependent manner, with maximum stimulation seen at high dose cyclosporine (1000 ng/ml). PGI2 release by cells grown in the presence of high dose cyclosporine was about threefold greater than that by control cells.
As shown in Table I , l0-M indomethacin, a known prostaglandin synthesis inhibitor, significantly reduced PG!2 release in both control and cyclosporine-treated cells. These data suggested that cyclosporine stimulated both PG!2 synthesis and release by microvascular endothelial cells.
Discussion
The present study has demonstrated that cyclosporine exerts direct effects on cultured microvascular endothelial cells. The dose range of cyclosporine used in this study were within the peak and nadir therapeutic plasma levels reported in patients receiving the medication either orally or intravenously [20, 21J. high concentrations of cyclosporine were found in many organs Similar cyclosporine concentrations have also been used in cell and tissues, notably liver, kidney, and retroperitoneal fat [20, culture studies [19] . When administered to humans or animals, 21]. In fact, animal data show that levels of cyclosporine in Electron microscopy demonstrated nonspecific cytoplasmic vacuolations with cyclosporine treatment. These ultrastructural changes corresponded to the cytoplasmic vacuolations visible on light microscopy. The observations are probably not artifactual since they were not present in control cells processed under identical conditions. Furthermore, the cytoplasmic changes were dependent on the dosage and duration of drug exposure. With high dose cyclosporine, the vacuoles appear to contain membrane fragments and other organized materials. These vacuoles resemble the morphological appearance of phagolysosomes, suggesting the sublethal damage of cyclosporine to susceptible endothelial cells. More importantly, we did not observe any swelling of or damage to mitochondria and other cytoplasmic organelles by cyclosporine treatment. A previous study on rats given very high doses of cyclosporine for three weeks also reported similar ultrastructural damages in rat proximal renal tubular cells [321. Unfortunately, glomerular endothelial cells were not examined by the investigators in that study. Our current findings are in sharp contrast from those of other studies on renal glomerular and tubular cells of cyclosporine-treated animals, which demonstrated mitochondrial swelling in addition to cytoplasmic vacuolations [7-101. It is possible that the observed mitochondrial swelling could be due to artifacts caused by improper fixation and processing of tissue samples.
The present findings indicate that cyclosporine is a potent inhibitor of microvascular endothelial cell replication. Our observations on inhibition of cell replication by cyclosporine are similar to those previously reported in EL4 cells from a thymic leukemia cell line, and murine islet cells [29, 31] . The mechanism whereby cyclosporine influences cell proliferation is not well understood. Cyclosporine does not prevent a cellular response by merely coating the cell surface, but probably acts via a series of specific intracellular events [1, 19] . Furthermore, it does not appear to affect the activation of calcium-dependent protein kinases or cyclic AMP-dependent protein kinases, at least in T lymphoblastoid cell lines [19] . Recent studies suggest that cyclosporine may bind to calmoduhin and act as a calmoduhin antagonist [30, 331 . Thus, cell replication may be interfered with through the calcium/calmodulin-dependent intracellular pathways, resulting in disruption of the cytoskeletal matrix. This molecular mechanism, which clearly requires [30, 31, 33, 34] .
Endothelial cells are an important source of prostacyclin (PGI2), a potent vasodilator that also inhibits thromboxanemediated platelet aggregation [161. These properties of PGI2 are thought to play important roles in protection against thrombosis and atherosclerotic cardiovascular disease [161. Recent work suggests that PGI2 may also have important implications for the regulation of renovascular resistance and for interactions with the renin-angiotensin system [14, 151. Indeed, PG!2 is capable of stimulating the renin-angiotensin-aldosterone system, while it also acts as a physiologic antagonist to angiotensin II in In cultured endothelial cells, PGI2 production is stimulated by exposure to a variety of agents, such as thrombin, trypsin, and the calcium ionophore A23187 [381. Cyclosporine, like some of these agents, also induces prostacyclin release by microvascular endothelial cells in culture. In the present study, the basal prostacyclin release by control cells was comparable to levels reported in endothelial cells cultured from both large and small vessels [17, 28] . In the presence of high dose cyclosporine, prostacyclin release per cell increased to almost threefold over the untreated controls. Since cyclosporine in the range of concentrations tested was not cytotoxic, it is unlikely 
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Prostacyclin release into the culture media was quantified daily for a total of 6 days. The representative data shown were obtained from 2. 4, and 6 days following the addition of cyclosporine (CsA) at the dosages indicated. Data are expressed as mean SEM of6 experiments and analyzed using Tukey's method for multiple comparisons.
n.d. = not detectable; and n.t. = not tested. a The effect of iO M indomethacin (+ I) is shown in the corresponding columns.
b Denotes statistical significance with P < 0.05 when compared with the respective controls.
that the increase in prostacyclin in the media could be attributed to cell leakage or release by dying cells. Furthermore, the level of prostacyclin release induced by cyclosporine was dosedependent, indicating a pharmacological effect on endothelial cells. Since indomethacin inhibited prostacyclin release in the culture medium, our current data implied that the cyclosporineinduced increase in prostacyclin release by microvascular endothelial cells is likely due to both increased synthesis and crovascular endothelial cells, the intensity and pattern of positive staining for Factor VIII antigen is not appreciably altered. This crude quantitative estimate may suggest that cyclosporine does not influence the amount of Factor VIII antigen production in small vessel endothelial cells.
The kidney, with its unique vascular supply and blood flow characteristics, has the largest vascular endothelial surface relative to weight of any organ in the body. Consequently, release.
exposure of the glomerular capillary network to toxic subWhile cyclosporine induces prostacyclin production by mi-stances occurs with much higher frequency compared with properties of these cells [37, 39] . Cyclosporine-induced nephrotoxicity in animals and humans is associated with abnormal structural changes in capillary, or renal tubules, or both [7] [8] [9] [10] .
As a result, cyclosporine could lead to both acute and chronic renal dysfunction. Divergent opinions exist with regards to whether the cyclosporine-induced toxicity arises primarily from endothelial damage, or from effects on tubular cells, or from both. Recent in vivo and in vitro studies, however, have failed to show any direct evidence of cyclosporine-induced injury on renal tubular cell injury [37] , thereby arguing against the concept of cyclosporine-induced toxic renal tubular injury as a primary event. Indeed, clinical studies on renal allograft recipients are consistent with this view. It has been observed that the urinary levels of the lysosomal enzyme, N-acetyl-/3-glucosaminidase (NAG), a sensitive marker of renal tubular injury, does not differ between patients treated with cyclosporine and those receiving azothiapnne, another immunosuppressant which does not cause appreciable renal damage [37] . Changes in the renal vasculature have been the focus of more recent studies on cyclosporine-induced toxicity. For example, cyclosporine reduces renal blood flow when infused in rats and humans [1, 2, 39], suggesting a predominant renovascular effect of the drug.
Several studies have suggested that cyclosporine inhibits the synthesis of a "prostacyclin-stimulating factor", possibly a lymphokine, thereby reducing the production of prostacyclin by the renal vascular endothelium [11-131. Based on this tenet, endothelial injury in the presence of reduced PGI2 would then progress to local capillary thrombosis and glomerular infarction similar to that seen in the generalized Schwartzman reaction [11, 12] . Experimental rabbit models have shown that cyclosponne reduces prostacyclin generation by vessel wall [11, 121. However, the source of production and identity of the so-called "prostacyclin-stimulating factor" remains elusive. On the other hand, some studies indicate that cyclosponne treatment is associated with a stimulation of renal prostaglandin synthesis, resulting in increased urinary excretion of prostacyclin [37] . These observations are supported by reports on the inhibition of prostaglandin synthesis by indomethacin, leading to an increase in renal toxicity with nontoxic doses of cyclosporine [39, 40] . Furthermore, cyclosporine has been reported to stimulate prostacyclin production in smooth muscle cells from guinea pig aorta, presumably through enhanced arachidonic acid release [411.
Our current data have clearly demonstrated that cyclosporine has two direct effects on microvascular endothelial cells: inhibition of cell replication and stimulation of prostacyclin release. Similar effects may also occur in renal microvascular endothehal cells. In view of our in vitro observations, it would be tempting to speculate on the cellular mechanisms of cyclosporine-induced nephrotoxicity and hypertension. Cyclosporine has diverse actions on different cell types, as evident by its multiple effects on various T lymphocytes [1] [2] [3] . Likewise, the pathogenesis of cyclosponne-induced nephrotoxicity is multifactoriaL It is conceivable that glomerular or capillary endothelial injury may be an initial lesion occurring as a result of anoxia or graft versus host disease. Since cyclosporine inhibits cell replication and stimulates prostacyclin production by endothelial cells, the overall effect of cyclosporine will depend on the extent of endothelial injury in vivo. Total prostacyclin production by renal endothelial cells may be decreased, unchanged, or even increased. If production is increased, which could occur if endothelial cell damage is minimal, cyclosporine treatment may lead to activation of the renin-angiotensin system and eventually hypertension [42] . This effect of cyclosporine may account for the experimental observation of increased renin level with its use [35, 36] , and the increased incidence of hypertension in several clinical studies [1] [2] [3] [4] [5] [6] [7] . On the other hand, through its direct inhibition on endothelial cell replication, cyclosponne may potentiate gbmerular endothelial injury in vivo by impairing the regenerative response of endothelium to wound. This may result in alterations in renal blood flow and glomerular filtration rate, both of which are well documented [7, 81 . Inhibition of endothelial cell replication could also result in a decrease in total prostacyclin production, as was observed in our experiments. Indeed, decreased urinary prostaglandins have been reported in patients receiving cyclosporine therapy [43] . Coupled with its possible toxic effect on the renal tubules, cyclosporine can generate a vicious cycle ultimately resulting in further renal damage.
Further studies using cultured microvascular endothelial cells will undoubtedly lend further insight into the molecular mechanisms of cyclosporine-induced prostacyclin synthesis by vascular cells.
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